Gadolinium contrast may link to life-threatening condition
The FDA is advising caution in the use of gadolinium contrast agents with MRI in patients with advanced kidney failure.
The FDA is advising caution in the use of gadolinium contrast agents with MRI in patients with advanced kidney failure.
The warning came after the Danish Medicines Agency reported that 25 patients with kidney failure developed a condition called nephrogenic systemic fibrosis/nephrogenic fibrosis dermopathy (NSF/NFD). All had recently undergone MR angiography with the gadolinium contrast agent Omniscan at medical centers in Denmark and Austria.
The condition causes fibrosis of the skin and connective tissues throughout the body. Patients with NSF/NFD may lose mobility of joints, and the fibrosis could spread to other parts of the body. Treatment options are limited, and the condition can be fatal.
The potential link between contrast and NSF/NFD was reported in Nephrology, Dialysis and Transplantation in January.
The FDA advises that in patients with advanced kidney failure, defined as those requiring dialysis or with a glomerular filtration rate of 15 cc/min, gadolinium contrast should be used only if clearly necessary. If contrast is used, the minimum dose should be administered. It may be wise for the patient to then promptly undergo dialysis.
Five agents with gadolinium are approved for use in MR imaging in the U.S.: Omniscan, OptiMARK, Magnevist, ProHance, and MultiHance. The FDA has not approved gadolinium contrast agents for MRA, which can require three times the dose of MRI.
The FDA is now investigating all gadolinium contrast agents to determine whether they do in fact cause the condition in patients with renal failure, as this patient group was not typically represented in premarketing studies.
It's possible that other factors in the patients' histories caused NSF/NSFD, according to the FDA.
Cases of NSF/NFD should be reported to the FDA Medwatch.
For more information, see the Diagnostic Imaging archives:
Expanding contrast options widen clinical utility of MRA
Dynamic contrast-enhanced MR imaging finally comes of age
Berlex recalls tainted lot of Ultravist CT contrast media
Could Ultrafast MRI Enhance Detection of Malignant Foci for Breast Cancer?
April 10th 2025In a new study involving over 120 women, nearly two-thirds of whom had a family history of breast cancer, ultrafast MRI findings revealed a 5 percent increase in malignancy risk for each second increase in the difference between lesion and background parenchymal enhancement (BPE) time to enhancement (TTE).
MRI Study Suggests Shape of White Matter Hyperintensities May Be Predictive of Cognitive Decline
April 7th 2025Emerging research demonstrated that cognitive declines in memory, executive function and processing speed domains were associated with irregular shape of periventricular/confluent white matter hyperintensities.
Can Abbreviated MRI Have an Impact in Rectal Cancer Staging?
April 4th 2025Abbreviated MRI demonstrated a 95.3 percent specificity for rectal cancer and provided strong agreement with the full MRI protocol for T staging and detection of extramural venous invasion, according to newly published research.
